AV
Alexandria Venture Investments
Pasadena, California, United StatesFounded 1996
Alexandria Venture Investments focuses on early- to growth-stage companies across life science, agriculture, technology, and sustainability sectors. Their strategy involves making strategic investments and leveraging their parent company's extensive ecosystem to foster innovation and growth within their portfolio.
90% of their portfolio is in Biotech & Life Sciences. Deal activity increased 57% year-over-year (11 deals in the last 12 months). Their most common stage is series-a (51% of deals). Average disclosed round size is $59.8M (across 40 rounds with reported amounts).
Portfolio
41
Fund Size
$1.6B
Top Stage
Series A
Last 12 Mo
11
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
41 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Precede Biosciences | Series B | $63.5M | Jan 2026 |
 Recludix Pharma | Unknown | — | Jan 2026 |
| SSolve Therapeutics, Inc. | Series D | $120M | Nov 2025 |
 Accipiter Biosciences | Seed | $12.7M | Nov 2025 |
 Tr1X, Inc. | Series C | $50M | Oct 2025 |
 Crystalys Therapeutics Inc. | Series A | $205M | Sep 2025 |
 Dualitas Therapeutics, Inc. | Series A | $65M | Sep 2025 |
| LLeal Therapeutics, Inc. | Series A | $30M | Aug 2025 |
| RRemedy Plan Therapeutics | Series A | $18M | May 2025 |
 Hoofprint Biome | Series A | $15M | Apr 2025 |
 Solu Therapeutics | Series A | $41M | Apr 2025 |
 Umoja Biopharma | Series C | $100M | Jan 2025 |
| AAutoimmunity BioSolutions | Seed | $2M | Nov 2024 |
 Axonis Therapeutics | Series A | $115M | Oct 2024 |
| AArchon Bioscience | Seed | $20M | Oct 2024 |
| LLeal Therapeutics, Inc. | Series B | $45M | Oct 2024 |
 March Biosciences | Series A | $28.4M | Oct 2024 |
 Ability Biologics | Seed | $18M | Jun 2024 |
| EElo Life Systems | Series A | $20.5M | Jan 2024 |
| Tr1X, Inc. | Series A | $75M | Jan 2024 |
 Bitterroot Bio | Series A | $145M | Jun 2023 |
| PParatus Sciences | Series D | $100M | Feb 2023 |
 Aspen Neuroscience | Series B | $147.5M | May 2022 |
 Pheast Therapeutics | Series A | $76M | Apr 2022 |
 Creyon Bio | Seed | $40M | Mar 2022 |
Page 1 of 2
Top Co-Investors
ARCH Venture Partners8 shared
OrbiMed6 shared
DCVC Bio4 shared
Casdin Capital4 shared
Sofinnova Partners4 shared
Flagship Pioneering4 shared
Novo Holdings3 shared
The Column Group3 shared
Leaps by Bayer3 shared
Eli Lilly and Company3 shared
Chugai Venture Fund3 shared
GV (Google Ventures)2 shared
Mirae Asset2 shared
Euclidean Capital2 shared
Atlas Venture2 shared
Access Biotechnology2 shared
Cormorant Asset Management2 shared
MRL Ventures Fund2 shared
Qiming Venture Partners USA2 shared
Newpath Partners2 shared
Last updated: 5 March 2026